CN1189097A - 用于治疗肺病的二核苷酸 - Google Patents

用于治疗肺病的二核苷酸 Download PDF

Info

Publication number
CN1189097A
CN1189097A CN96195028A CN96195028A CN1189097A CN 1189097 A CN1189097 A CN 1189097A CN 96195028 A CN96195028 A CN 96195028A CN 96195028 A CN96195028 A CN 96195028A CN 1189097 A CN1189097 A CN 1189097A
Authority
CN
China
Prior art keywords
chemical compound
patient
lung
pharmaceutically acceptable
described patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN96195028A
Other languages
English (en)
Other versions
CN1086940C (zh
Inventor
M·J·斯图兹三世
R·C·小保彻尔
E·R·拉萨罗斯基
C·A·格里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CN1189097A publication Critical patent/CN1189097A/zh
Application granted granted Critical
Publication of CN1086940C publication Critical patent/CN1086940C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明公开了式(Ⅰ)化合物或其药学上可接受的盐。在式(Ⅰ)化合物中,n为1—6;n优选为2—4,最优选为4。X为－OH或－SH,优选－OH。A和B各自独立地选自(a)和(b),其中R为H或Br。该化合物可用于治疗气道疾病如囊纤维变性。另外公开了包含药学上可接受的载体(例如固体或液体载体)和上述式(Ⅰ)化合物的药物制剂。还公开了水化需要治疗的患者肺中的粘液分泌物的方法,包含给予该患者的肺部上述式(Ⅰ)化合物。给药步骤可以通过吸入来完成。

Description

用于治疗肺病的二核苷酸
发明领域
本发明涉及某种二核苷酸，含有其的药物制剂，以及通过给患者服用二核苷酸而从该患者的肺中去除残留粘液分泌物的方法。
发明背景
本发明是以由国家健康学会授予的Grant No.MHLBIHL34322的政府资助形式完成的。政府对本发明拥有一定权利。
在囊纤维变性中，气道上皮的几项机能是异常的，CL-转运和Na+吸收方面的缺陷已在文献中详细记载。参见，例如：Knowles等人，科学221，1067(1983)；Knowles等人，临床研究杂志71，1410(1983)。调整离子转运对以上皮离子转运异常为特征的肺病如囊纤维变性可能会有潜在的治疗效果。
在囊纤维变性和其他肺病中的一个治疗目的是，改变粘液的水含量使肺粘液分泌物水化，以便该分泌物随后可以更容易地通过mucociliaryaction或简单的咳嗽而从肺中除去。美国专利No.4,501,729中公开了利用烟雾化的阿米洛利来水化粘液分泌物。阿米洛利似乎可阻断Na+通过气道上皮细胞重吸收，并由此抑制水从粘液中的吸收。
涉及ATP或UTP给药的技术例举了水化肺粘液分泌物的不同治疗方法，它们似乎刺激了呼吸上皮细胞的氯化物分泌。参见，例如：Boucher的美国专利No.5,292,498。
考虑到大量受囊纤维变性困扰的病人，非常需要一种新的方法，以提供水化肺粘液分泌物的方法并由此促进肺粘液的清除。
发明概述
本发明的第一个方面是式(I)化合物或其药学上可接受的盐：在式I化合物中：
n为1-6。n优选为2-4，最优选为4。
X为-OH或-SH，优选-OH。
A和B各自独立地选自下列成员：
Figure A9619502800082
其中R为H或Br。
本发明的第二个方面是药物制剂，其包含处于药学上可接受的载体(例如固体或液体载体)中的、有效量的可水化肺粘液分泌物的上述式(I)化合物或其药学上可接受的盐。任意地，该药物制剂可以进一步包含选自下列成员的化合物：有效量的阿米洛利、苯沙明和非那明，以抑制水从肺粘液分泌物中的重吸收。
本发明的第三个方面是水化需要治疗的患者的肺中的粘液分泌物的方法，包括给予该患者的肺有效量的可水化肺粘液分泌物的上述式I化合物或其药学上可接受的盐。
本发明的第四个方面是上述式I化合物或其药学上可接受的盐在制备用于水化需要治疗的患者的肺中的粘液分泌物的药剂中的用途。
在下面的说明书中详细解释了本发明的上述及其他目的和方面。
附图说明
图1显示二核苷酸A2P4对预先用弗司扣林治疗的气道上皮的腔表面上CL-分泌物的作用。
图2显示A2P4给药对预先用UTP刺激的气道上皮中CL-分泌物的作用。
发明详述
本发明方法可用于促进(即增强、加速、帮助)粘液分泌物从因为各种原因而需要治疗的患者的肺中的清除，包括(但不限于)由于气管疾病如囊纤维变性、慢性支气管炎、哮喘、支气管扩张、手术后肺膨胀不全(手术后气道被残留的分泌物堵塞)和卡塔格内综合征等而产生的残留分泌物。
本发明主要与人的治疗有关，但也可为了兽医的目的而用于其他哺乳动物如狗和猫的治疗。
式I化合物及其药学上可接受的盐(即活性化合物)可以按照本文中描述的技术和对本领域技术人员来说对其做了显然的改变后的方法来制备。例如，UppppU(U2P4)的合成可以通过利用水溶性碳化亚胺EDC(1-乙基-3-〔3-二甲基-氨-丙基〕-碳化亚胺盐酸化物)来缩合UDP而完成。参见：K.E.Ng和L.E.Orgel，核酸研究15(8)，3572-80(1987)。
阿米洛利及其在水化肺粘液分泌物中的用途是已知的，并公开于Boucher和Knowles的美国专利N0.4,501,729中(本文中引用的所有专利文献都是以其全部内容结合于本文中作为参考的)。苯沙明(也称作3，5-二氨基-6-氯-N-〔苄氨基氨基亚甲基〕吡嗪羰酰胺)和非那明(也称作3，5-二氨基-6-氯-N-〔苯氨基氨基亚甲基〕吡嗪羰酰胺)是已知化合物并公开于E.Cragoe的美国专利No.3,313,813中。本文中所用的术语“苯沙明”、“非那明”和“阿米洛利”包括其药学上可接受的盐(即上述盐)，例如(但不限于)盐酸阿米洛利、盐酸苯沙明或盐酸非那明。
如上所述，本发明的活性化合物可以制备成其药学上可接受的盐。药学上可接受的盐是能保留该化合物预期的生物活性且不会产生不希望的毒性作用的盐。这样的盐的实例是：(a)与无机酸例如盐酸、硫酸、磷酸、硝酸等形成的酸加成盐；与有机酸诸如乙酸、草酸、酒石酸、琥珀酸、马来酸、富马酸、葡糖酸、柠檬酸、苹果酸、抗坏血酸、苯甲酸、单宁酸、棕榈酸、藻酸、聚谷氨酸、萘磺酸、甲磺酸、对甲苯磺酸、萘二磺酸、聚半乳糖醛酸等形成的盐；和(b)从元素阴离子如氯、溴和碘形成的盐。
本文中公开的活性化合物可以通过任何适宜的方式给予患者的肺，但优选通过由该活性化合物组成的可呼吸的颗粒的气溶胶悬液形式给药，患者将其吸入。该可呼吸的颗粒可以是液体或固体。
包含活性化合物的液体颗粒的气溶胶可通过任何适宜的方式生产，如用压力驱动的气溶胶喷雾器或超声波喷雾器。参见，例如：美国专利No.4,501,728。喷雾器是商业上可获得的设备，它通过一个窄的文氏管口加速压缩气体、一般空气或氧气，或通过超声波搅动而将活性成分的溶液或悬液转化为治疗气溶胶雾。用于喷雾器的合适的制剂由处于液体载体中的活性成分组成，包含的活性成分最多为该制剂40％W/W，但优选小于20％W/W。该载体通常为水(最优选无菌、无焦精水)或稀释的醇水溶液，优选通过添加例如氯化钠而制成与体液等渗压的。如果该制剂不是无菌制备的话，则任意的添加剂包括防腐剂例如羟基苯甲酸甲酯，还包括抗氧化剂、调味剂、挥发油、缓冲剂和表面活性剂。
包含活性化合物的固体颗粒的气溶胶可用任何固体颗粒药剂气溶胶发生器进行同样的制备。用于患者固体颗粒药剂给药的气溶胶发生器生成如上所解释的可呼吸的颗粒，并以适于人给药的速度产生含有预定剂量药剂的气溶胶体积。固体颗粒气溶胶发生器的一个直观类型是吹入器。适于通过吹入给药的制剂包括精细粉碎的粉末，它可利用吹入器传送或以嗅的方式进入鼻腔。在吹入器中，粉末(例如定量的、可有效进行本文所述治疗的粉末)被包含在一般由明胶或塑料制成的胶囊或盒中，它们可就地贯穿或打开并通过吸气设备或以人工操作的抽气机方式通过抽气而传送该粉末。应用于吸入器中的粉末可以仅由活性成分组成，或由包含活性成分、合适的粉末稀释剂如乳糖以及任意的表面活性剂的粉末搀和物组成。包含的活性成分一般为该制剂的0.1-100W/W。气溶胶发生器的第二种直观类型包括定量吸入器。定量吸入器是压缩气溶胶分配器，一般含有处于液体推进剂中的活性成分的悬液或溶液制剂。在使用这些设备过程中，通过适于传送预定体积，一般是10-150μL的阀门排出该制剂以产生含有活性成分的细颗粒雾。合适的推进剂包括某些含氯氟烃化合物，例如二氯二氟甲烷，三氯氟甲烷，二氯四氟乙烷及其混合物。该制剂还可含有一种或多种共溶剂例如乙醇，表面活性剂如油酸或脱水山梨醇三油酸，抗氧化剂和合适的调味剂。
气溶胶，无论固体还是液体颗粒形成，都可由气溶胶发生器生产，速率为每分钟大约10-150升，更优选每分钟约30-150升，最优选每分钟约60升。含较大量药剂的气溶胶可更快进行。
式I化合物或其药学上可接受的盐的剂量将根据所治疗的病情和患者的状态而变化，但一般该量应足以使活性化合物在患者的气道表面上达到的溶解浓度为约10-7-约10-3摩尔/升，更优选约10-6-约3×10-4摩尔/升。根据所给药活性化合物的颗粒制剂的溶解度，日剂量可以分为一个或几个单位剂量给药。根据患者的年龄和病情，以用于人的可呼吸颗粒计，日剂量可以是约1-20mg(重量)。与式I化合物或其盐同时给药的阿米洛利、苯沙明或非那明的剂量可以与式I化合物或其盐的剂量相同。
含有本发明活性剂的固体或液体颗粒药物制剂应包括可呼吸的颗粒，也就是说，颗粒的尺寸应足够小以随着吸气而通过嘴和喉并进入支气管和肺泡。一般说来，大小为1-5微米(更特别是小于约4.7微米)的颗粒是可呼吸的。包括于气溶胶中的不可呼吸大小的颗粒容易沉积在咽和喉中，不可呼吸大小的颗粒在气溶胶中的数量优选减至最小值。对于鼻腔给药来说，颗粒大小优选为10-500μm以确保其保留在鼻腔中。
在本发明制剂的制造中，活性剂或其生理上可接受的盐或游离碱，除了别的物质以外，一般是与可接受的载体混合在一起的。当然，该载体必须是在与制剂中的任何其他成分相容的意义上可接受的，且必须是对病人无害的。该载体可以是固体或液体或两者都有，并优选与化合物配制成单位剂量制剂，例如胶囊，它可含有0.5％-99％(重量)的活性化合物。在本发明的制剂中可以掺合一种或多种活性化合物，制剂可以利用任何一种已知的主要由将各成分混合而组成的制药技术来制备。
通过用研钵和研杵来研磨活性化合物可以缺得含有活性化合物的可呼吸的干燥颗粒的组合物，然后将该微粉化的组合物通过400目筛以分散或分离出大的烧结物。
用于制备本发明组合物的阿米洛利、苯沙明和非那明可以选择以苯沙明或非那明的药学上可接受的游离碱形式存在。因为该化合物的游离碱的溶解性小于盐，应用游离碱组合物可使苯沙明或非那明更持久地释放进肺部。以还未进入溶液的微粒形式存在于肺中的阿米洛利、苯沙明或非那明是不可能产生生理应答的，但可作为逐渐进入溶液中的生物可利用药物的保管处。
药物组合物可任意含有用来促进气溶胶形成的分散剂。合适的分散剂是乳糖，它可以任何适宜的比例(例如重量比1∶1)与苯沙明或非那明混合。
在下面非限制性实施例中将更加详细地解释本发明。实施例1二核苷酸A2P4对氯(CL-)分泌物的作用
在可渗透的支持体上培养普通气道细胞并按照M.J.Stutts等人，美国生理学杂志267，C1442-C1451(1994)中描述的方法测定CL-分泌物。给予二核苷酸A2P4(Sigma Chemicals，St.Louis，MO)后测定CL-分泌物。加入阿米洛利以阻断气道上皮的钠吸收。当接触气道上皮处理的底外侧表面时，A2P4只有很小的作用，但对已用弗司扣林治疗过的腔表面则在气道上皮中刺激出更多CL-分泌物。这一结果显示于图1。因为弗司扣林最大地活化了CFTR介导的cAMP调节的气道上皮的CL- 通道，这一结果表明A2P4刺激了腔purigenic P2U受体。
此外，A2P4给药对于事先用已知可活化非CFTR CL-通道的UTP刺激的气道上皮中的CL-分泌物没有影响。显示于图2中的这些结果表明，可通过A2P4调节受purigenic受体控制的非CFTR CL-通道，并进一步表明：A2P4刺激了与通过P2U受体起作用的UTP相同的气道上皮CL-通道。这一受体的激发是某些肺病包括囊纤维变性的治疗策略。
上述实施例是对本发明的举例说明，而对本发明没有限制作用。通过下述权利要求定义了本发明，相当于该权利要求包括在本文中。

Claims (21)

1.式(I)化合物或其药学上可接受的盐：
Figure A9619502800021
其中：n为1-6；
  X为-OH或-SH；
  A和B各自独立地选自下列成员：
Figure A9619502800022
其中R为H或Br。
2.按照权利要求1的化合物，其中n为4。
3.按照权利要求1的化合物，其中A和B选自尿苷和5-溴尿苷。
4.按照权利要求1的化合物，其中A和B为腺苷。
5.按照权利要求1的化合物，其中X为-OH。
6.一种药物制剂，包含处于药学上可接受的载体中的、有效量的可水化肺粘液分泌物的式(I)化合物或其药学上可接受的盐：
Figure A9619502800031
其中：n为1-6；
  X为-OH或-SH；
  A和B各自独立地选自下列成员：
Figure A9619502800032
其中R为H或Br。
7.按照权利要求6的药物制剂，进一步包含以有效量给予所述患者的可抑制水从肺粘液分泌物中重吸收的化合物，其选自下列成员：阿米洛利、苯沙明和非那明。
8.按照权利要求6的药物制剂，其中所述载体为液体载体。
9.按照权利要求6的药物制剂，其中所述载体为固体微粒载体。
10.水化需要治疗的患者的肺中的粘液分泌物的方法，包含给予该患者的肺部有效量的可水化肺粘液分泌物的下述式I化合物或其药学上可接受的盐：其中：n为1-6；
  X为-OH或-SH；
  A和B各自独立地选自下列成员：
其中R为H或Br。
11.按照权利要求10的方法，其中所述化合物是通过给予由所述化合物组成的可呼吸颗粒的气溶胶悬液而传送到所述患者肺部的。
12.按照权利要求11的方法，其中所述颗粒选自固体颗粒和液体颗粒。
13.按照权利要求11的方法，其中所述气溶胶是由粒子大小为约1-10微米的颗粒组成的。
14.按照权利要求10的方法，其中所述化合物以足以使其在所述患者的气道表面上达到的浓度为约10-7-约10-3摩尔/升的量给药。
15.按照权利要求10的方法，进一步包含以有效量同时给予所述患者的可抑制水从肺粘液分泌物中重吸收的化合物，其选自下列成员：阿米洛利、苯沙明和非那明。
16.治疗需要治疗的囊纤维变性病人的方法，包含通过将可呼吸颗粒的气溶胶悬液吸入所述患者的呼吸系统而给药，所述颗粒由下述式I化合物或其药学上可接受的盐组成：其中：n为1-6；
  X为-OH或-SH；
  A和B各自独立地选自下列成员：
Figure A9619502800052
其中R为H或Br，用量为可水化所述患者肺中残留肺粘液分泌物的有效量，并由此使该残留粘液分泌物更容易地经mucociIiary action而从肺部除去。
17.按照权利要求16的方法，其中所述化合物是通过给予由所述化合物组成的可呼吸颗粒的气溶胶悬液而传送到所述患者肺部的。
18.按照权利要求17的方法，其中所述颗粒选自固体颗粒和液体颗粒。
19.按照权利要求17的方法，其中所述气溶胶是由粒子大小为约1-10微米的颗粒组成的。
20.按照权利要求16的方法，其中所述化合物以足以使其在所述患者的气道表面上达到的浓度为约10-7约10-3摩尔/升的量给药。
21.按照权利要求16的方法，进一步包含以有效量同时给予所述患者的可抑制水从肺粘液分泌物中重吸收的化合物，其选自下列成员：阿米洛利、苯沙明和非那明。
CN96195028A 1995-06-07 1996-06-06 用于治疗肺病的二核苷酸 Expired - Fee Related CN1086940C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/486,988 US5635160A (en) 1995-06-07 1995-06-07 Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US08/486,988 1995-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB021191085A Division CN1181088C (zh) 1995-06-07 1996-06-06 用于治疗肺病的二核苷酸

Publications (2)

Publication Number Publication Date
CN1189097A true CN1189097A (zh) 1998-07-29
CN1086940C CN1086940C (zh) 2002-07-03

Family

ID=23933941

Family Applications (2)

Application Number Title Priority Date Filing Date
CN96195028A Expired - Fee Related CN1086940C (zh) 1995-06-07 1996-06-06 用于治疗肺病的二核苷酸
CNB021191085A Expired - Lifetime CN1181088C (zh) 1995-06-07 1996-06-06 用于治疗肺病的二核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021191085A Expired - Lifetime CN1181088C (zh) 1995-06-07 1996-06-06 用于治疗肺病的二核苷酸

Country Status (14)

Country Link
US (4) US5635160A (zh)
EP (1) EP0831777B1 (zh)
JP (1) JPH11506790A (zh)
KR (1) KR100414699B1 (zh)
CN (2) CN1086940C (zh)
AT (1) ATE231519T1 (zh)
AU (1) AU696845B2 (zh)
BR (1) BR9609063A (zh)
CA (1) CA2223894C (zh)
DE (1) DE69625906T2 (zh)
ES (1) ES2189874T3 (zh)
MX (1) MX9709637A (zh)
NO (1) NO975632L (zh)
WO (1) WO1996040059A1 (zh)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
AU716486B2 (en) * 1995-04-13 2000-02-24 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
US5908611A (en) * 1995-05-05 1999-06-01 The Scripps Research Institute Treatment of viscous mucous-associated diseases
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US6420347B1 (en) * 1997-03-27 2002-07-16 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
DE69736468T2 (de) * 1996-03-27 2007-03-29 Inspire Pharmaceuticals, Inc. Verfahren zur behandlung der ziliardyskinesie mit uridintriphosphaten und verwandten verbindungen
US6673779B2 (en) * 1996-03-27 2004-01-06 Inspire Pharmaceuticals, Inc. Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
DK0981534T3 (da) * 1997-02-06 2006-09-04 Inspire Pharmaceuticals Inc Dinukleotider og deres anvendelser
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6998121B2 (en) 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
GB9711848D0 (en) * 1997-06-06 1997-08-06 William Harvey Research Limite Treatment and prophylaxis of infraction
AU8351498A (en) * 1997-07-17 1999-02-10 William Harvey Research Limited Use of adenosine tri- or tetra-phosphates and their analogues for the reatment of cerebral infarction
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
BRPI9810436B1 (pt) * 1997-07-25 2015-12-29 Inspire Pharmaceuticals Inc processo para a produção em larga escala de di (5'-tetrafosfato de uridina) e sais do mesmo
US6548658B2 (en) * 1997-07-25 2003-04-15 Inspire Pharmaceuticals, Inc. Di-(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
EP1011688B1 (en) * 1997-08-29 2005-02-02 The University of North Carolina at Chapel Hill Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases
US6251930B1 (en) 1997-10-23 2001-06-26 Southern Research Institute Activating C1- secretion
JP4633927B2 (ja) 1998-05-22 2011-02-16 インスパイアー ファーマシューティカルズ，インコーポレイティド 治療用ジヌクレオチドおよび誘導体
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
CN100354296C (zh) * 1998-10-02 2007-12-12 雅玛山酱油株式会社 二尿苷四磷酸或其盐的晶体和其制备方法、以及制备该化合物的方法
WO2000023023A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
EP2258183A1 (en) 1998-12-22 2010-12-08 The University of North Carolina at Chapel Hill Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs
MXPA01008547A (es) * 1999-02-26 2003-06-06 Inspire Pharmaceuticals Inc Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
WO2000075365A2 (en) * 1999-06-08 2000-12-14 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
EP1196396B1 (en) 1999-07-19 2008-03-26 University Of North Carolina At Chapel Hill Pharmacologically active compounds with two covalently linked active principles (sodium channnel blocker/p2y2 receptor agonist) for the treatment of mucosal surfaces
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
AU2001230533A1 (en) * 2000-02-04 2001-08-14 Kissei Pharmaceutical Co. Ltd. Powdered preparation for inhalation and powder inhalant containing the same packed
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
ES2689704T3 (es) * 2000-11-30 2018-11-15 Vectura Limited Partículas para usar en una composición farmacéutica
EP1920763B2 (en) 2000-11-30 2022-06-15 Vectura Limited Pharmaceutical compositions for inhalation
EP1368366A1 (en) * 2001-02-07 2003-12-10 Celltech R & D Limited Non-natural nucleotides and dinucleotides
US7109181B2 (en) 2001-06-25 2006-09-19 Inspire Pharmaceuticals, Inc. Joint lubrication with P2Y purinergic receptor agonists
WO2003011885A1 (en) * 2001-07-25 2003-02-13 Celltech R & D Limited Non-natural carbon-linked nucleotides and dinucleotides
TW200300692A (en) * 2001-11-06 2003-06-16 Inspire Pharmaceuticals Inc Method for treating or preventing inflammatory diseases
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) * 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
JP2007524379A (ja) * 2003-03-31 2007-08-30 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン 上皮ナトリウムチャンネル関連障害のＰｈａｒｍｉｃｏ−遺伝子治療
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
CA2651180A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to alter virus infection
WO2008024169A1 (en) * 2006-07-21 2008-02-28 Glsynthesis, Inc. Reactive pyrophosphoric and bisphosphonic acid derivatives and methods of their use
CA2747188C (en) 2008-11-20 2017-06-13 Glsynthesis Inc. Antithrombotic diadenosine tetraphosphates and related analogs
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
SG11201407875UA (en) 2012-06-08 2014-12-30 Aduro Biotech Compostions and methods for cancer immunotherapy
CN103184067A (zh) * 2012-08-23 2013-07-03 中国海洋石油总公司 一种延长重整生成油分子筛精制催化剂使用寿命的方法
WO2014093936A1 (en) 2012-12-13 2014-06-19 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
PT2931713T (pt) 2012-12-17 2017-02-22 Parion Sciences Inc Derivados de cloro-pirazina carboxamida úteis para o tratamento de doenças favorecidas por insuficiente hidratação das mucosas
BR112015014178A2 (pt) 2012-12-17 2017-07-11 Parion Sciences Inc compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
CN105358158A (zh) 2013-04-29 2016-02-24 纪念斯隆-凯特琳癌症中心 用于改变第二信使信号传导的组合物和方法
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
GB201406225D0 (en) * 2014-04-07 2014-05-21 Hall Roderick L Treatment for respiratory disease
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
AU2017229347A1 (en) 2016-03-07 2018-11-01 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
KR102504764B1 (ko) * 2017-06-21 2023-03-02 주식회사 종근당 디뉴클레오사이드 폴리포스페이트 화합물의 제조방법
KR20210110055A (ko) * 2020-02-28 2021-09-07 주식회사 종근당바이오 P1, p4-디(우리딘 5'-)테트라포스페이트 나트륨염 4 수화물 결정형 a의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE639386A (zh) * 1962-10-30
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4855304A (en) * 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
JP3481236B2 (ja) * 1990-10-05 2003-12-22 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 固体粒状薬剤及び固体粒状薬剤エーロゾル投薬装置
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
CN1398873A (zh) 2003-02-26
WO1996040059A1 (en) 1996-12-19
DE69625906T2 (de) 2003-11-13
JPH11506790A (ja) 1999-06-15
MX9709637A (es) 1998-07-31
NO975632L (no) 1998-02-03
CN1086940C (zh) 2002-07-03
BR9609063A (pt) 1999-01-26
US20010041682A1 (en) 2001-11-15
ATE231519T1 (de) 2003-02-15
US5635160A (en) 1997-06-03
CA2223894C (en) 2007-12-04
CN1181088C (zh) 2004-12-22
DE69625906D1 (de) 2003-02-27
EP0831777A4 (zh) 1998-05-06
AU696845B2 (en) 1998-09-17
CA2223894A1 (en) 1996-12-19
AU6176496A (en) 1996-12-30
NO975632D0 (no) 1997-12-04
US5935555A (en) 1999-08-10
KR19990022296A (ko) 1999-03-25
US6235266B1 (en) 2001-05-22
KR100414699B1 (ko) 2004-05-31
ES2189874T3 (es) 2003-07-16
EP0831777A1 (en) 1998-04-01
EP0831777B1 (en) 2003-01-22

Similar Documents

Publication Publication Date Title
CN1086940C (zh) 用于治疗肺病的二核苷酸
DE69426459T2 (de) Verbesserung in verbindung mit trägerpartikeln zur verwendung in trockenpulverinhalatoren
DE69925849T2 (de) Verabreichung von einem aerosolisierten wirkstoff unter moduliertem strömungswiderstand
DE69631786T3 (de) Über die lungen verabreichbares trockenpulver alpha 1-antitrypsin
DE69332240T2 (de) Ultrafeines pulver zur inhalation und dessen herstellung
DE69934435T2 (de) Methoden zum befeuchten der nasenschleimhaut
DE69737510T2 (de) Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
DE69511374T2 (de) Neue und verbesserte aminoglykosidformulierung als aerosol
KR100910888B1 (ko) 에어로졸화 이송을 위한 적절한 토브라마이싱의 조성물
DE69218329T2 (de) Verabreichungsverfahren von Dipalmitoylphosphatidylcholindispersionen
DE69738000T2 (de) Neue Arzneiformulierung enthaltend Budesonide
DE69725160T2 (de) Verwendung von uridin-triphosphat verwandte verbidungen zur prävention und behandlung von pneumonie in immobilisieren patienten
DE69533128T2 (de) Pharmazeutische akzeptabel dnase zusammensetzung
CH685229A5 (de) Ciclosporin zur pulmonalen Verabreichung.
DE69724991T2 (de) Behandlung von bronchitis mit diuridintretraphosphat
DE69511279T2 (de) Verwendung von flüssigen fluorcarbonen zur förderung der arzneistoffabgabe an den lungen
AU771984B2 (en) Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
WO2005037246A2 (de) Wässrige aerosol-zubereitung
CH693763A5 (de) Verwendung eines Antibiotikums zur Herstellung eines Medikamentes zur Behandlung von schwerer chronischer Bronchitis (Bronchiektase).
DE69210802T2 (de) Pharmazeutische aerosolzubereitung sowie deren verwendung zur behandlung und prophylaxe viraler erkrankungen
EP1673074B1 (de) Flüssige zubereitung enthaltend tobramycin
DE69527713T2 (de) Verbindunngen und zusammensetzungen zur verabreichung via inhalation und insufflierung
KR20140001877A (ko) 흡입 데누포솔에 의한 낭포성 섬유증의 치료 방법
DE60022070T2 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen
JPH01228912A (ja) エアロゾル形態のペンタミジンを用いるニユーモシスチス・カリニ肺炎の予防方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1017843

Country of ref document: HK

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee